November 13, 2025 – Zug, Switzerland: In keeping with its commitment to patient-centered care and equitable access to innovative cancer treatments, RGCC has announced the initiation of legal proceedings aimed at addressing the limited access of thousands of EU patients to EMA-approved Advanced Therapy Medicinal Products (ATMPs).

This initiative focuses on ensuring that all EU citizens, regardless of their country of residence, have equal access to EMA-approved therapies in line with the 20-year-old Directive 2004/23, as well as Regulation (EU) 2024/1938. These frameworks establish the legal basis for equal access to ATMPs, which have shown significant therapeutic potential for cancer and other diseases.

While several EU Member States, including Germany, Austria, and the Netherlands, have already made such therapies available, other nations have yet to implement the necessary frameworks, leaving many patients without access to potentially transformative treatments.

“Our position has always been clear; patients must come first,” said Dr. Ioannis Papasotiriou, Founder and Director of RGCC. “We view this step as an ethical obligation to the patients who place their trust in us. We are committed to working constructively with authorities and stakeholders to ensure that access to advanced therapies is a right equally shared by all.”

Over the past two years, RGCC has engaged with relevant national and EU authorities to highlight discrepancies in the implementation of the aforementioned regulations, in addition to the implementation of Regulation 1394/2007, and to offer scientific and regulatory expertise in support of compliance. Despite these efforts, continued inaction and inconsistent application of EU law have prevented many patients from receiving approved therapies that could improve outcomes and quality of life.

Through this initiative, RGCC aims to promote transparency and collective action toward a fair and unified approach to healthcare access across the EU.

About RGCC International:

RGCC was launched in 2004 by genetics pioneer Dr. Ioannis Papasotiriou who believes that the key to effectively treating cancer lies in personalized medicine. Today, RGCC is a leading innovator in the field of oncology diagnostics. Using world-leading technology, equipment, and innovative techniques, our team of scientists has developed a range of liquid biopsies that help physicians track cancer progression and tailor treatment plans based on individual patient profiles.

For general inquiries, please contact: [email protected]